Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
In the Toc Regulator Mode
2022-03-12
In the “Toc34 Regulator Mode” (Fig. 6), recognition of the transit peptide by Toc159 monomer (step 4) leads to heterodimer-formation [18]. Subsequently, preprotein interaction with the Toc34G homodimer (step 1) regulates the Toc34G homodimer (step 2, 3). However, this mode requires a parallel induct
-
Like tBHQ and DEM treatment of
2022-03-12
Like tBHQ and DEM, treatment of Keap1+/+ MEFs with SFN increased the abundance of Hmox1 and Nqo1 mRNA, and this was blunted by LY294002 and MK-2206 (Figure 2C). However, unlike the situation with tBHQ and DEM, treatment of Keap1−/− MEFs with SFN did not increase further the elevated basal levels of
-
R R MNF is a unique bitopic agent with
2022-03-12
(R,R′)-MNF is a unique bitopic agent with selective and potent β2AR agonistic and GPR55 inhibitory properties [10], [11] that are independently associated with the drug's anti-mitotic and anti-tumorigenic actions. In 1321N1, U118MG, and melanoma cell lines, (R,R′)-MNF activation of the β2AR decrease
-
dexamethasone acetate FOLE was recently approved for use in
2022-03-12
FOLE was recently approved for use in PN-dependent patients in the United States. However, potential adverse effects of FOLE, including bleeding risk, and effects on the immune system [8], [39], render its use in certain patient populations controversial. Identification of key downstream modulators
-
br Experimental br Acknowledgment This work was supported
2022-03-12
Experimental Acknowledgment This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Glyoxalase I (GLO1) is a zinc enzyme that catalyzes the isomerization of a hemithioacetal, formed from glut
-
ATP is essential for maintaining
2022-03-12
ATP is essential for maintaining the ionic balance of the lens (Michael and Bron, 2011). Without sufficient ATP there is an ionic imbalance due to Na+K+ATPase dysfunction. Previous studies have shown that rabbit lenses incubated ex vivo without glucose rapidly lost ATP in their lens epithelium and f
-
br Acknowledgments This research was supported by a grant fr
2022-03-12
Acknowledgments This research was supported by a grant from the Korea Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI17C0616). Dr. Jun-Mo Yang was supported by the Natio
-
This study was approved by our institutional ethics committe
2022-03-12
This study was approved by our institutional ethics committee, and informed consent was obtained from each participant or legal guardian. We performed whole-genome SNP genotyping in the one unaffected and two affected siblings by using the Illumina Human 610 Genotyping BeadChip panel, which interrog
-
GK also called hexokinase IV or D is a glycolytic
2022-03-12
GK, also called hexokinase IV or D, is a glycolytic enzyme that converts metalloproteinase to glucose-6-phosphate. GK has unique characteristics compared with those of the ubiquitously expressed hexokinase isoforms I–III, and is predominantly expressed in the pancreas and liver. In pancreatic β-cel
-
GCK MODY is the most common form of MODY
2022-03-12
GCK-MODY is the most common form of MODY diabetes in many populations (Chevre et al., 1998; Massa et al., 2001; Barrio et al., 2002; Estalella et al., 2007; Pruhova et al., 2010; Capuano et al., 2012; Giuffrida et al., 2017). However, data about GCK-MODY among North African populations are very rare
-
Knowing that our strongest phenotypic differences between th
2022-03-12
Knowing that our strongest phenotypic differences between the genotypes involved feeding behavior in various contexts, we decided to examine the case of restricted feeding and food anticipatory activity. Animals faced with a restricted schedule of food availability develop a series of anticipatory b
-
br Acknowledgements We thank the following individuals
2022-03-12
Acknowledgements We thank the following individuals for notable contributions to this work: Dr. Ruth Wood, Dr. Alan Watts, Dr. Casey Donovan, Andrea Suarez, Emily Nakamoto, Allison Apfel, April Banayan, and Jonathan Cheung. This study was supported by the National Institute of Health grants, DK10
-
Both anxiety like behavior and sucrose preference intake
2022-03-12
Both anxiety-like behavior and sucrose preference/intake were reduced in GPR40/FFAR1 KO male mice, while social behavior was normal in KO mice. These findings indicate that brain GPR40/FFAR1 is involved in the modulation of anxiety- and depression-like behavior in rodents. Previous studies have demo
-
To understand the structural basis for the mode
2022-03-11
To understand the structural basis for the mode of action of indole-based compounds the crystal structures of bound to both the wild type and A128T IN CCDs have been solved. The X-ray crystallography studies have revealed that binds at the IN dimer interface in the principal LEDGF/p75 binding pock
-
GSK dimethylpiperidin yl butoxy phenyl piperidine carbonyl n
2022-03-11
GSK-835726 (3-[4-[4-[4-[4-(3,3-dimethylpiperidin-1-yl)butoxy]phenyl]piperidine-1-carbonyl]naphthalen-1-yl]propanoic acid) is a dual H1/H3 receptor antagonist with the potential to be used in allergic rhinitis. Likewise GSK-1004723, the drug-likeness criteria have not been passed by this drug candida
14259 records 464/951 page Previous Next First page 上5页 461462463464465 下5页 Last page